{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:44:23Z","timestamp":1790444663313,"version":"4.1.0"},"reference-count":91,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Sports Med"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the current evidence and applications of injectable peptide therapy, focusing on its potential in regenerative medicine and sports performance, to help orthopaedic providers better understand the current state of different therapeutic peptide approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>Narrative review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted using PubMed to identify biochemical and clinical studies on the most popular types of injectable peptide therapy. Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability. TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports. CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies. Tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Despite the popularity of these peptides in mainstream media and among patients, significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03635465251357593","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T08:00:51Z","timestamp":1767254451000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians"],"prefix":"10.1177","volume":"54","author":[{"given":"Cory K.","family":"Mayfield","sequence":"first","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna K.","family":"Bolia","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailan L.","family":"Feingold","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Lin","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Liu","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Rick Hatch","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth C.","family":"Gamradt","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Weber","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00201.2006"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030336"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-08057-9_22"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1054\/ghir.2001.0239"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081081"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-014-2030-8"},{"issue":"4","key":"e_1_3_2_8_2","first-page":"554","article-title":"Banting\u2019s, Best\u2019s, and Collip\u2019s accounts of the discovery of insulin","volume":"56","author":"Bliss M.","year":"1982","unstructured":"Bliss M. Banting\u2019s, Best\u2019s, and Collip\u2019s accounts of the discovery of insulin. Bull Hist Med. 1982;56(4):554-568.","journal-title":"Bull Hist Med"},{"issue":"1","key":"e_1_3_2_9_2","article-title":"The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice: the effect of N(G)-nitro-L-arginine methyl ester and L-arginine","volume":"12","author":"Boban-Blagaic A","year":"2006","unstructured":"Boban-Blagaic A, Blagaic V, Romic Z, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice: the effect of N(G)-nitro-L-arginine methyl ester and L-arginine. Med Sci Monit. 2006;12(1):BR36-BR45.","journal-title":"Med Sci Monit"},{"key":"e_1_3_2_10_2","unstructured":"Bulk drug substances used in compounding under Section 503A of the FD&C Act. US Food and Drug Administration. January 7 2025. Available at: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/bulk-drug-substances-used-compounding-under-section-503a-fdc-act. Accessed February 11 2025."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.006411"},{"key":"e_1_3_2_12_2","unstructured":"Center for Drug Evaluation and Research. Warrior Labz SARMS - 655280 - 06\/12\/2023. US Food and Drug Administration. June 20 2023. Available at: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/warrior-labz-sarms-655280-06122023. Accessed February 11 2025."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.21107"},{"key":"e_1_3_2_14_2","unstructured":"Certain bulk drug substances for use in compounding that may present significant safety risks. US Food and Drug Administration. September 27 2024. Available at: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Accessed February 11 2025."},{"key":"e_1_3_2_15_2","unstructured":"ConjuChem places DAC:GRF program in HIV lipodystrophy on clinical hold. Available at: https:\/\/www.bioworld.com\/articles\/590432-conjuchem-places-dac-grf-program-in-hiv-lipodystrophy-on-clinical-hold. Accessed November 12 2024."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/11202240-000000000-00000"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0061322"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97233"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102485"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05483.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1402"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.10.003"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1011617"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.7.2172"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2012.09.043"},{"key":"e_1_3_2_26_2","unstructured":"Infront G. World Anti-Doping Agency (WADA) Prohibited List. US Anti-Doping Agency. May 1 2019. Available at: https:\/\/www.usada.org\/athletes\/substances\/prohibited-list\/. Accessed October 5 2024."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1702"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2013.04.014"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1054\/ghir.1999.9998"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2010.07.005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.17245\/jdapm.2022.22.2.97"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.09.017"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062166"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.20096"},{"issue":"4","key":"e_1_3_2_35_2","first-page":"8","article-title":"Intra-articular injection of BPC 157 for multiple types of knee pain","volume":"27","author":"Lee E","year":"2021","unstructured":"Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13.","journal-title":"Altern Ther Health Med"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/19476035241276406"},{"key":"e_1_3_2_37_2","unstructured":"Lim S Biologics T. Overview of the regulatory framework and FDA\u2019s guidance for the development and approval of biosimilar and interchangeable products in the US. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Overview-of-the-Regulatory-Framework-and-FDA\u2019s-Guidance-for-the-Developmet-and-Approval-of-Biosmiliar-and-Interchangeable-Products-in-the-US.pdf. Accessed February 12 2025."},{"issue":"2","key":"e_1_3_2_38_2","first-page":"501","article-title":"Functional peptides for cartilage repair and regeneration","volume":"10","author":"Liu Q","year":"2018","unstructured":"Liu Q, Jia Z, Duan L, Xiong J, Wang D, Ding Y. Functional peptides for cartilage repair and regeneration. Am J Transl Res. 2018;10(2):501-510.","journal-title":"Am J Transl Res"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00730"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3436"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-4179(01)00055-9"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/mtomcs\/mfae019"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0715"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.3109\/15419060009015002"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-007-3706-2"},{"key":"e_1_3_2_46_2","unstructured":"Office of the Commissioner. FDA warns US Stem Cell Clinic of significant deviations. US Food and Drug Administration. March 24 2020. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-warns-us-stem-cell-clinic-significant-deviations. Accessed February 11 2025."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200523180301"},{"key":"e_1_3_2_48_2","unstructured":"Peptide therapeutics market. Transparency Market Research. Available at: https:\/\/www.transparencymarketresearch.com\/peptide-therapeutics-market.html. Accessed October 5 2024."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44050130"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0060070"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2003.11.005"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071987"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics2030236"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.2950"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124033"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1390552"},{"key":"e_1_3_2_57_2","unstructured":"Reference product exclusivity for biological products filed under Section 351(a) of the PHS Act. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/reference-product-exclusivity-biological-products-filed-under-section-351a-phs-act. Accessed November 1 2024."},{"key":"e_1_3_2_58_2","unstructured":"Regulation of human cells tissues and cellular and tissue-based products (HCT\/Ps): Small Entity Compliance Guide. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance. Accessed November 1 2024."},{"key":"e_1_3_2_59_2","article-title":"A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis","volume":"128","author":"Ruenzi M.","year":"2005","unstructured":"Ruenzi M. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology. 2005;128:A584.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.13.040173.000253"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(98)00180-X"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180712110447"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1159\/000093982"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0928-4257(93)90038-U"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)00796-9"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01033-9"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-4179(03)00004-4"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112696"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40883-019-00129-y"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03060260063027"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008976"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.756111"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.20089"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-0266(03)00110-4"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1536"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvq115"},{"issue":"100293","key":"e_1_3_2_77_2","first-page":"100293","article-title":"Novel wellbeing and repair peptide use in the UK: netnographic findings","author":"Turnock LA","year":"2024","unstructured":"Turnock LA, Hearne E. Novel wellbeing and repair peptide use in the UK: netnographic findings. Perform Enhanc Health. 2024;(100293):100293.","journal-title":"Perform Enhanc Health"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9070822"},{"key":"e_1_3_2_79_2","article-title":"Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers","volume":"51","author":"Veljaca M.","year":"2003","unstructured":"Veljaca M. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut. 2003;51:A309.","journal-title":"Gut"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)24349-X"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-006-3498-9"},{"issue":"1","key":"e_1_3_2_82_2","article-title":"Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats: a cytoprotection viewpoint","volume":"75","author":"Vukusic D","year":"2024","unstructured":"Vukusic D, Zenko Sever A, Sever M, et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats: a cytoprotection viewpoint. J Physiol Pharmacol. 2024;75(1).","journal-title":"J Physiol Pharmacol"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00904-4"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.157686"},{"issue":"1","key":"e_1_3_2_85_2","first-page":"48","article-title":"TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer","volume":"7","author":"Wong HY","year":"2022","unstructured":"Wong HY, Wang GM, Croessmann S, et al. TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Signal Transduct Target Ther. 2022;7(1):48.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.03.026"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104665"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i7.1032"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1159\/000445578"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S208600"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.66.4.1170"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111660"}],"container-title":["The American Journal of Sports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03635465251357593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03635465251357593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03635465251357593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:26:26Z","timestamp":1779269186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03635465251357593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/03635465251357593"],"URL":"https:\/\/doi.org\/10.1177\/03635465251357593","relation":{},"ISSN":["0363-5465","1552-3365"],"issn-type":[{"value":"0363-5465","type":"print"},{"value":"1552-3365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}